This week, financing news in the biopharmaceutical sector has arrived:

eight innovative companies, including Huode Biotech, Deep Cell, and Zhongke Aoge, have successively secured financing ranging from tens of millions to several hundred million yuan. Capital precisely focuses on core tracks such as iPSC cell therapy, AI pharmaceuticals, xenotransplantation, and high-end medical devices, continuously empowering underlying technology transformation and clinical commercialization, highlighting the long-term value of the industry.

1. Huode Biotech completes the first round of nearly 200 million yuan Series C financing, accelerating the development

of iPSC neurotherapy products. On August 10, Zhejiang Huode Bioengineering Co., Ltd., focusing on the development of iPSC-derived general-purpose cell therapy products, officially announced the completion of the first round of nearly 200 million yuan in Series C financing. This round was jointly funded by new shareholders Tasly Capital, Haibang Investment, Guangzhou Health Industrial Investment, and longmen Capital with consecutive capital increases. The funds will be directed toward advancing clinical development in core pipelines and building commercial production systems, demonstrating the investment community’s high recognition of its technological path and commercialization potential.

As a benchmark enterprise in the domestic iPSC neuronal cell therapy sector, Huode Biotech was established in 2017. Relying on its self-built full-chain iPSC technology platform, it has accumulated strong patent barriers. Its core pipeline, hNPC01 injection, is currently one of the fastest-progressing iPSC neuronal cell products of its kind worldwidePositive Phase I clinical data have been disclosed for the sequelae of ischemic stroke hemiplegia, and multiple special FDA certifications have been obtained, validating the advancement of the company’s technological approach and strategic planning from both clinical and regulatory perspectives.

In addition to its core pipeline, Huode Biotech has completed forward-looking layouts in multiple neuro-disease cell therapy segments. This is the third round of capital increases by existing shareholder Longmen Capital, demonstrating its continued long-term value and capital trust. After this round of financing, the company will further accelerate clinical progress for its core products, simultaneously advance commercial capacity layout, lay a solid foundation for subsequent product launches and market expansion, and is expected to become the first core player in China’s general iPSC cell therapy field to achieve commercial implementation.

2. Deep Cell completes nearly 100 million yuan seed round financing; “AI + physics” breaks through drug design

Recently, innovative company Deep Cell focused on AI pharmaceuticals and virtual cell tracks announced the completion of nearly 100 million yuan in seed financing. This round was jointly led by Zhongke Chuangxing and other institutions, with core founder Dr. Xu Shihao also recently appearing on CCTV’s entrepreneurship talk show. The related technology layout and development plans have attracted widespread industry attention.

As one of the few domestic biopharmaceutical innovation entities deeply engaged in the “deep integration of AI and molecular physics” technology route, Deep Cell anchors its core development goal of “making AI a new type of research entity in the life sciences field,” adopting a “dual-track approach of deep and shallow parallel” technological breakthroughs:

• The first is the “pursuit of extreme depth” direction. The team focuses on common industry pain points such as insufficient accuracy and limited generalization of existing AI molecular models, deeply coupling AI algorithms with underlying molecular physics laws to build a high-precision molecular design platform centered on intelligent molecular interaction base models. This can effectively improve the accuracy of druggability prediction for candidate drug molecules and significantly reduce the cycle and trial-and-error costs of early-stage drug discovery;
• The second is the “Extreme Broadness” direction. The team is building a virtual cell world model driven by multi-omics data and physical rules, achieving continuous iterative optimization through a unified learning framework. The ultimate goal is to connect multi-scale simulation chains from molecular and subcellular to cellular levels, building an intelligent simulation system covering the entire drug development chain.
  Representatives of this round of investors all stated that Deep Cell’s technology layout directly addresses the core shortcomings of the current AI pharmaceutical field’s “emphasis on data fitting, neglect of underlying physical laws.” The technical challenges it overcomes possess strong foundational value and long-term barriers, and the company is expected to grow into a globally competitive core technology platform amid the wave of life sciences intelligence.

3. Yimingkai completes a strategic capital increase of tens of millions of yuan, accelerating the layout

of non-tumor pipelines. Recently, domestic innovative biopharmaceutical company Yimingkai officially disclosed that its wholly-owned subsidiary, Yimingkaier, a platform company focused on innovative drug R&D in the non-tumor field, successfully signed strategic capital increase agreements on August 6 with multiple external professional investment institutions and independent industry investors. Successfully completed a strategic round financing worth tens of millions of yuan, with all funds to be used for pipeline R&D and clinical advancement of innovative macromolecule drugs in the cardiovascular and metabolic disease fields, injecting core momentum into the group’s long-term development strategy driven by “oncology + non-oncology.”

As a specialized R&D entity officially established in January 2024, Yimingkaier leverages Yiming Onke’s mature macromolecule drug R&D technology foundation validated through oncology pipelines to quickly build a differentiated non-tumor pipeline matrix. Its core project advancement efficiency leads the same stage of startup platforms: its cardiovascular candidate IMC-003 has already completed a Phase I single-dose escalation study first. Multiple dose-escalation phase trials have been officially launched, with preclinical data showing that its efficacy potential far exceeds that of similar products under investigation; The synchronously deployed cardiovascular pipeline IMC-004 has also entered the critical preclinical validation stage.

In the broad market segment of metabolic diseases and weight loss and muscle gain, Yimingkeer’s two candidate drugs, IMC-011 and IMC-015, have both completed core proof of concept and are actively advancing IND application preparations. Tian Wenzhi, Chairman of Yiming Onke, stated that this strategic capital increase is a key milestone in the group’s diversified pipeline layout. Subsequently, funds will be pooled to efficiently advance the clinical transformation of core projects, striving to become a benchmark enterprise in the domestic field of non-tumor macromolecule innovative drugs.

4. Xenotransplantation Leader Zhongke Aoge Completes Over 200 Million RMB in Series A3 Financing

Recently, Zhongke Aoge, a leading domestic company in the xenotransplantation sector, officially announced the completion of over 200 million RMB in Series A3 financing. This round was led by hard technology investment institution Zhongke Chuangxing, with multiple professional industry investment institutions co-participating. At the same time, existing shareholders continued to increase their holdings, with Kaicheng Capital serving as the exclusive financial advisor for this round of financing. The funds raised this time will mainly be invested in two core directions: first, advancing multi-center clinical trials of core pipeline xenotransplantation products; second, expanding standardized breeding capacity for clinical-grade donor pigs, laying a solid supply foundation for subsequent commercialization.

As a benchmark enterprise in the field of xenotransplantation in China, Zhongke Auge has deep core technical barriers: the company’s founder, Professor Pan Dengke, is recognized in the industry as the “China’s number one cloned pig.” In the early stages of entrepreneurship, he overcame multiple industry challenges, successfully secured the core donor pig population, and established the country’s first large-scale clinical-grade donor pig breeding baseTaking the lead in achieving stable bulk supply of clinical-grade donor pigs. On the technical side, the company has built a full-chain technical capability covering gene editing, donor cultivation, and transplantation adaptation, and has now established the largest low-immunogenicity donor pig population in China; From 2025 to 2026, the company’s scientific research achievements were intensively implemented: successfully completing multiple clinical trials of pig kidney transplantation in humans, the gene-edited pig liver transplantation project was selected as one of the annual “Top Ten Scientific Advances in China,” and the survival time of pig kidney transplant recipient monkeys exceeded 648 days, setting a global leading record for similar research.

According to the company’s development plan, it will promote the formal entry of xenogeneic kidney transplantation into key clinical trials within 2-3 years, and achieve clinical application of this technology within 5 years. The completion of this round of financing will provide ample financial support for the implementation of this strategic goal and also demonstrates the high recognition by industry capital of Zhongke Aoge of Zhongke Aoge’s technological strength and the commercialization prospects of the xenotransplantation track.

5. Spatial intelligence technology company Ommo completes tens of millions of dollars in Series A financing

On August 7, Ommo, a technology company focused on spatial intelligence, officially completed tens of millions of dollars in Series A financing. This round was jointly led by Hong Kong Dingpei Group and leading well-known funds, with Kangjun Capital adding as a participation, and Dianshi Capital serving as the exclusive financial advisor for the transaction. The funds raised this time will be directed toward two core directions: first, the technical iteration and upgrade of the core self-developed spatial positioning system; second, the establishment and improvement of a large-scale mass production system, while accelerating the commercialization of related products in high-value scenarios such as embodied intelligence and healthcare.

Currently, the AI industry is accelerating its penetration from digital virtual scenarios into the physical world. High-precision, robust spatial perception capabilities have become the core foundational support for the large-scale implementation of embodied intelligence. Ommo has taken the exclusive lead in permanent magnet spatial sensing technology, creating a full-stack 3D tracking platform that adapts to various unstructured and complex work environments. It has already completed commercial validation in medical precision navigation scenarios and is gradually expanding into multi-track areas such as home service robots and industrial intelligent manufacturing. The company’s core team possesses a distinct international and platform-based technical background, possessing strong cross-domain collaboration capabilities in key areas such as spatial sensing algorithms, multimodal data fusion, and scenario adaptation and debugging, building a technology moat that is difficult to replicate.

The investors in this round stated that Ommo’s self-developed spatial sensing system simultaneously meets multiple core industry requirements such as positioning accuracy, environmental anti-interference capability, and low deployment cost. Its vast accumulated proprietary scenario algorithms and spatial data form a strong competitive barrier. The technological breakthrough has broken the previous boundaries of spatial sensing solutions, offering long-term growth potential in golden sectors such as smart healthcare and embodied intelligence; The exclusive financial advisor also clearly pointed out that the complete originality of Ommo’s underlying technology and its broad market adaptation are the core logic behind its capital support.

6. After half a year, Mingche Technology secures additional capital investment, completing tens of millions of yuan in Series A+ financing

. Recently, Mingche Biotechnology (Suzhou) Co., Ltd., focusing on high-end minimally invasive ophthalmic treatment devices, officially announced the completion of tens of millions of yuan in Series A+ financing. This round was led by Yuansheng Venture Capital, a domestic professional institution deeply rooted in the medical and health sector. This marks the company’s return to capital investment after half a year, demonstrating the industry’s high recognition of its technological path and commercialization prospects.

The funds raised this time will focus on advancing key nodes in two core pipelines: first, the domestic and international registration and certification of the core product, the minimally invasive glaucoma drainage tube (MIGS); second, the R&D and clinical progress of the lens posterior chamber refractive lens (ICL), which is a popular track for lenses. As an innovative ophthalmic device company established in 2021, Mingche Technology has built a comprehensive eye health platform product matrix covering both the anterior and posterior segments, with its R&D team leading the industry in technical accumulation and implementation capabilities.

In the past six months, the company’s core pipelines have made consecutive breakthrough progresses: the minimally invasive glaucoma drainage tube has initiated CE certification, the upgraded product stands out in minimally invasive adaptability and IOP regulation stability, and the supporting implantable intraocular pressure sensor is simultaneously advancing FDA certification, with technical barriers leading similar domestic pipelines; In response to the current blue ocean track where the domestic ICL market has long been monopolized by imported brands and continues to grow rapidly, Mingche Technology’s self-developed ICL uses exclusive patented optical materials and has already completed its own production line, with the potential to break the import monopoly. Yuansheng Venture Capital stated that it will leverage its own industrial resources and join hands with Mingche Technology to jointly promote the innovative implementation of domestic high-end ophthalmic devices and the global market layout.

7. Zheyuan Technology secures nearly 200 million yuan in Series A2 financing, advancing AI4S platform construction

Domestic biomedical technology company Zheyuan Technology, focusing on the “AI4S + disease” track, recently announced the completion of nearly 200 million yuan in Series A2 financing, led by Shengxiang Bio and its industrial fund, with participation from hard technology investment institution Zhongke Chuangxing and othersThe funds will be specifically allocated to three main directions: high-value innovative IP output, AI4S (AI4S (AI-driven scientific discovery) platform upgrades, and the industrialization and transformation of core technological achievements.

As the first domestic innovator to deploy large models in the life sciences field, Zheyuan Technology’s core technological barriers have formed differentiated advantages: its self-built “Life World Model” platform has completed a full-stack technology upgrade, officially forming five types of foundational models covering multidimensional biological signal analysis. This system is an upgraded and iterative upgrade of the original AI-assisted drug R&D technology framework. It provides computing power and algorithm support for the entire process of innovative drug R&D at the underlying logic level.

Relying on this foundational technology, Zheyuan Technology has built a closed-loop service system covering the entire drug discovery cycle, capable of delivering standardized solutions from target discovery to candidate compound generation (D2P), and from research hypothesis to industry transformation (T2I). The company’s first independently developed new drug based on this platform has successfully entered Phase I clinical trials, and multiple differentiated innovation pipelines are progressing according to nodes. This financing also marks that Zheyuan Technology’s technology implementation capabilities have received multiple recognitions from industrial capital, hard technology investment institutions, and regional innovation ecosystems. The company will further leverage its core technological advantages to further drive trillion-yuan industrial transformation opportunities in the life and health sector.

8. Heluo Xintu completes 150 million RMB Pre-A round financing, deepening its original iPSC cell technology

. On August 7, Heluo Xintu, a leading innovative company in the iPSC artificial blood track, officially announced the completion of a 150 million RMB Pre-A round financing. This round was jointly led by Yifeng Capital, which is deeply engaged in the biopharmaceutical hard tech sector, and Minjin Investment, a professional investment platform under Nanjing State-owned Capital. Early investor Shunwei Capital continues to increase its investment.

As an original technology-driven company founded in 2021 led by Dr. Wang Wenyuan, Heluo Xintu stands out for its core barriers: it is one of the very few biopharmaceutical companies worldwide to successfully enter human clinical trials for iPSC artificial regenerative plateletsRelying on fully autonomous and controllable original iPSC underlying technology, it has built a standardized artificial blood mass production platform, addressing long-standing unresolved clinical pain points such as large supply gaps, limited matching fitting, pathogen contamination risks, and unstable production capacity in traditional blood donation models. Currently, the company has built a full-chain self-developed technology system, forming a collaborative development pattern of “100% self-supplied and self-developed upstream core raw materials + rapid clinical implementation of innovative downstream blood products.” At the same time, it has proactively positioned itself in key raw material tracks that have been bottlenecks in the CGT industry, successfully breaking the long-standing market monopoly of overseas giants in this field.

According to official disclosures, the funds raised in this round will focus on advancing clinical trials for iPSC artificial regenerative platelets, optimizing mass production platform processes, and preparing for the commercialization of upstream raw material pipelines. Each investor will leverage their advantages in industrial resources, clinical matchmaking, and state-owned endorsement to provide comprehensive empowerment for Heluo Xintu’s technology transformation and business expansion, accelerating the industrialization process of domestic artificial blood.

END

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: info@meritsip.com

© 2025 MeritsIP. All Rights Reserved.